Ascentage Pharma Group International (HK:6855) has released an update.
Ascentage Pharma Group International has reported a significant increase in revenue to RMB823.7 million for the first half of 2024, a 477.2% jump compared to the same period in 2023. The surge is attributed to sales of their pharmaceutical products, including the flagship drug olverembatinib, and a lucrative option agreement with Takeda Pharmaceuticals. Additionally, the company has made advancements in clinical trials for other key assets, indicating a robust period of growth and expansion.
For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.
